WWW.THESIS.XLIBX.INFO
FREE ELECTRONIC LIBRARY - Thesis, documentation, books
 
<< HOME
CONTACTS



Pages:     | 1 |   ...   | 87 | 88 || 90 | 91 |   ...   | 181 |

«PacifiCare’s medical management guidelines represent the recommendation of the PacifiCare Medical Management Guideline (MMG) committee. They are ...»

-- [ Page 89 ] --

The Her Option™ Uterine Cryoblation Therapy™ System received premarket approval (PMA) on April 20, 2001. The Dysfunctional Uterine Bleeding and Uterine Fibroids- Commercial Medical Management Guideline device is a closed-cycle cryosurgical device intended to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia due to benign causes for whom childbearing is complete. See the following Web site for more information: http://www.fda.gov/cdrh/mda/docs/p000032.pdf. Accessed April 2009.

The Accuprobe®for use in general and plastic surgery including gynecological procedures. See the following Web site for more information: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm. Accessed April 2009.

Devices for thermal ablation of the endometrium are regulated by the FDA as Class III devices that are subject to the most extensive regulations enforced by the FDA. The Gynecare ThermaChoiceTM device for thermal balloon endometrial ablation (TBEA) (Ethicon Inc.) and the Hydro ThermAblatorTM device (BEI Medical Systems) for hydrothermal endometrial ablation (HTEA) have received premarket approval from the FDA.

U.S. Food and Drug Administration (FDA) [Web site]. Searchable PMA database scanned for Product Codes MNB (Thermal endometrial ablation device) and MKN (Thermal balloon endometrial ablation device). Updated July 7, 2003.

Available at: http://www.accessdata. fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm. Accessed April 2009.

The MIRENA© received FDA approval on December 8, 2000 for use as an intrauterine contraceptive. The only indication included in the FDA-approved labeling is for use of this IUD as a contraceptive. Therefore, its use for treating dysfunctional uterine bleeding (DUB) would be considered an off-label use. The FDA does not impose restrictions on how

a licensed physician can use or prescribe an approved device. See the following Web site for more information:

http://www.fda.gov/cder/da/da1200.htm. Accessed April 2009.

The NovaSureTM Impedance Controlled Endometrial Ablation System (Novacept Inc., purchased by Pfizer Inc.) received FDA approval on September 28, 2001 for ablation of the endometrial lining of the uterus in premenopausal women with

menorrhagia secondary to DUB for whom childbearing is complete. See the following Web site for more information:

http://www.fda.gov/cdrh/pdf/p010013.html. Accessed April 2009.

A second device, the VESTA DUB endometrial ablation system was the first FDA-approved radio frequency endometrial device (Vesta Medical Inc., purchased by Pfizer Inc.). Pfizer, Inc. acquired Vesta Medical, Inc. in 1996, and clinical trial information was available until 2000. A search of the Pfizer, Inc. Web site did not identify any additional information, and there is no indication that this device is currently being marketed in the United States or Europe.

Uterine artery embolization (UAE) is a procedure and, therefore, not subject to FDA regulation. However, the embolic agents used are subject to FDA oversight. A number of agents are approved by the FDA for embolization procedures of the neurological system, but several have been specifically approved for UAE. Embosphere® Microspheres (Biosphere Medical, Inc.) received 510(k) approval on November 22, 2002, specifically for use in embolization of symptomatic uterine fibroids. Embosphere Microspheres are small spheres comprised of acrylic polymer and porcine-derived gelatin.

Although they are available in different sizes, the manufacturer states that only microspheres 500 or greater should be used for UAE. On March 26, 2004, Contour SE™ Microspheres and Contour™ Emboli PVA (Boston Scientific Corp.) also received 510(k) approval, with approved indications listed as embolization of hypervascular tumors, including leiomyoma

uteri, and arteriovenous malformations. See the following Web site for more information:

http://www.fda.gov/cdrh/pdf3/k034068.pdf. Accessed April 2009.

The Cryo-Hit(TM) System (Galil Medical Ltd.) first received 510(k) approval from the FDA on July 1, 1998. Modified versions of the device received 510(k) approval on July 12, 1999 and October 30, 2001. The device is intended for the cryosurgical destruction of tissue during gynecological procedures as well as in general, dermatological, neurosurgical, thoracic, oncological, rectal, and urological surgeries.

U.S. Food and Drug Administration (FDA) [Web site]. Center for Devices and Radiological Health (CDRH) page. 510(k)

approvals. K012497. Updated January 6, 2003. Available at:

Dysfunctional Uterine Bleeding and Uterine Fibroids- Commercial Medical Management Guideline http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm. Accessed April 2009.

U.S. Food and Drug Administration (FDA) [Web site]. Center for Devices and Radiological Health (CDRH) page. 510(k)

approvals. K980913. Approval summary. Updated January 6, 2003. Available at:

http://www.fda.gov/cdrh/pdf/K980913.pdf. Accessed April 2009.

The Signa Profile/i Magnetic Resonance System (GE Medical Systems Inc.) received 510(k) approval on September 8, 1999 as an open, whole-body scanner for use in diagnostic imaging and interventional procedures performed with MRcompatible devices.

See the following Web site for more information:





- http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/ pmn.cfm. Accessed April 2009. (K992135) http://www.fda.gov/cdrh/pdf/K992135.pdf. Accessed April 2009 In June 2004, the Signa Excite 1.5T MR system received FDA marketing clearance to aid in diagnosis via the 510(k) process. This clearance requires system use by a physician trained in diagnostic imaging of internal structures and organs.

In October 2004, InSightec received marketing approval for the ExAblate 2000 System from FDA through the PMA process.

Research Evidence Background Abnormal uterine bleeding in women of childbearing age is defined as any change in menstrual period frequency or duration, a change in amount of flow, or any bleeding between cycles. In postmenopausal women, abnormal uterine bleeding includes vaginal bleeding 12 months or more after the cessation of menstruation, or unpredictable bleeding in patients who have been receiving hormone therapy for 12 months or more. Abnormal uterine bleeding terms include oligomenorrhea (bleeding occurs at intervals of more than 35 days), polymenorrhea (bleeding occurs at intervals of less than 21 days), menorrhagia (bleeding occurs at normal intervals but with heavy flow or duration of more than 7 days), menometrorrhagia (bleeding occurs at irregular, noncyclic intervals and with heavy flow or duration more than 7 days), and metrorrhagia (irregular bleeding occurs between ovulatory cycles) (Milliman Care Guidelines) Menorrhagia can be idiopathic or can be associated with underlying uterine lesions such as fibroids or polyps, pelvic pathology, anatomical abnormalities, systemic illness, hormonal imbalance, or certain medications. Idiopathic menorrhagia that is not related to a specific underlying condition is called dysfunctional uterine bleeding (DUB). All these conditions associated with menorrhagia can be referred to as dysfunctional uterine bleeding, although it is also possible to have some conditions such as fibroids or an anatomical abnormality with normal menses. The focus in this policy is on treatment options when the bleeding pattern is abnormal.

Uterine fibroids (also known as leiomyomata) are benign tumors of the uterus. They have a rich blood supply and may cause excessive uterine bleeding, uterine enlargement, and mass or bulk related symptoms such as pelvic pain and pressure, urinary frequency and abdominal distension.

Conservative management of DUB includes watchful waiting and pharmacological therapy. Another treatment option is dilation and curettage. Hysterectomy is available when symptoms cannot be controlled by conservative treatment.

Conservative management of symptomatic fibroids includes watchful waiting and hormonal therapy. Hormone therapy causes the fibroids to shrink; however they will quickly return to their original mass once therapy has been discontinued.

Hysterectomy has been the primary treatment for symptomatic or rapidly enlarging fibroids. Hysteroscopic removal of fibroids has been the procedure of choice for those women who want to maintain their fertility, but this is a demanding and lengthy procedure and sometimes more difficult to perform than a hysterectomy and does not prevent the recurrence of fibroids. The resulting endometrial cavity may be problematic for fertility.

Alternate minimally invasive techniques have emerged. An advantage of these procedures over hysterectomy is that they do not involve surgical removal of the uterus; therefore, the operative and recovery times are shorter and the complication Dysfunctional Uterine Bleeding and Uterine Fibroids- Commercial Medical Management Guideline rates seem to be lower. Some may be performed as outpatient procedures, avoiding the hospital stay required after hysterectomy.

Endometrial cryoablation (ECA): In this procedure, a cryoprobe introduced through the vagina under ultrasound guidance delivers extreme cold (below -15° C to -20° C) in freeze-thaw cycles to the endometrium.

Thermal balloon endometrial ablation (TBEA): In this procedure, heat is delivered to the endometrial lining of the uterus via a latex balloon is filled with a small volume of sterile dextrose and water. The temperature of the fluid is raised by a heating element to 87 degrees C resulting in thermal coagulation of 3 to 5 mm of endometrium. A variation of this technique, hydrothermal endometrial ablation (HTEA), involves direct exposure of the uterine lining to saline heated to 90 degrees C.

Levonorgestrel-releasing intrauterine device (LNG-IUD: The local administration of the progestin levonorgestrel is delivered via an intrauterine device (IUD). The MIRENA© consists of a T-shaped polyethylene frame with a steroid reservoir around the vertical stem. The reservoir contains 52 mg of levonorgestrel, which is released at a dose of 20 ug per day. The local delivery of this hormone causes the endometrium to become insensitive to ovarian estradiol leading to atrophy of the endometrial glands, inactivation of the endometrial epithelium and suppression of endometrial growth and activity. The effects of this IUD last for approximately 5 years and are reversible upon removal of the IUD.

Radiofrequency endometrial ablation (RFA): This procedure uses a radiofrequency signal generator, a controller and a probe to generate heat in the uterus in an attempt to destroy the endometrial lining.

Uterine artery embolization (UAE): This procedure attempts to block the blood supply to uterine fibroid tumors thus promoting shrinkage through blood deprivation. For UAE to be effective, the arteries and their vascular beds must be completely occluded. The resultant ischemia can result in postembolization pain, but the abundant collateral blood supply in the pelvis protects against ischemic necrosis.

Magnetic resonance imaging (MRI)-guided cryoablation: This procedure is also known as interventional MRI (I-MRI) cryoablation. It uses a specially designed, i-MRI scanner to locate the fibroids and guide their cryosurgical destruction through a transabdominal percutaneous approach. Two major devices are used. The Cryo-Hit(TM) System consists of a structural enclosure, a power control panel, a computer and control assembly, gas supply and distribution systems, cryoprobes, temperature sensors, and a remote control unit. The Signa Profile/i Magnetic Resonance System has an open design and can be utilized during interventional procedures with MRI-compatible devices.

Magnetic resonance imaging (MRI)-guided focused ultrasound (FUA): This procedure combines real-time MRIguidance with high-intensity focused ultrasound for the noninvasive thermal ablation of uterine fibroids. Tumor ablation is performed by focusing a collection of ultrasonic beams to increase sonic beam intensity at a point deep within the tissue to cause thermal coagulation while sparing normal tissues.

Clinical Evidence Endometrial cryoablation (ECA) Searches of the published, peer-reviewed medical literature on endometrial cryoablation identified three single-center, prospective case series on the effectiveness of ECA for menorrhagia. The study populations ranged from 15 to 67 patients.( Rutherford, 1998; Kumar, 2002) Follow-up times ranged from 16 months or less to 22 months. Two additional studies (Duleba, 2003; Corson, 2001) were identified that evaluated outcomes at 1 and 2 years in patients participating in a multicenter, randomized controlled trial to compare the efficacy and safety of ECA with rollerball electroablation (RBEA) for treatment of menorrhagia. These studies were supported by the device manufacturer, CryoGen Inc. The study population consisted of 279 patients who were randomized to ECA or RBEA and followed up to 2 years. One study using ECA to treat fibroids was identified. (Zupi, 2005) Dysfunctional Uterine Bleeding and Uterine Fibroids- Commercial Medical Management Guideline Zupi et al. reported on cryomyolysis with the Her Option Cryoablation Unit for treatment of symptomatic uterine myomas in 20 menstruating women. (Zupi, 2005) At one year follow-up, all patients reported no bleeding and no myoma-related symptoms, comparable with patients who underwent hysterectomy. Mean reduction of myoma volume was 60% one year after surgery. No intraoperative or postoperative complications occurred.

American College of Obstetricians and Gynecologists (ACOG): The ACOG Guidelines for Women's Health (2002) state:

"Women who have failed medical therapy and no longer desire future childbearing are candidates for endometrial ablation, which appears to be an efficient and cost-effective alternative to hysterectomy for anovulatory uterine bleeding.



Pages:     | 1 |   ...   | 87 | 88 || 90 | 91 |   ...   | 181 |


Similar works:

«THE JOURNAL OF HYGIENE EDITED BY GEORGE H. F. NUTTALL, M.D., PH.D., Sc.D., F.R.S. QUICK PROFESSOR OF BIOLOGY IN THE UNIVERSITY OF CAMBRIDGE IN CONJUNCTION WITH JOHN S. HALDANE, M.D., LL.D., F.R.S. ARTHUR NEWSHOLME, M.D., F.R.C.P. READER IN PHYSIOLOGY IN THE MEDICAL OFFICER TO THE UNIVERSITY OF OXFORD LOCAL GOVERNMENT BOARD CHARLES J. MARTIN, M.B., D.Sc., F.R.S. DIRECTOR OF THE LISTER INSTITUTE OF PREVENTIVE MEDICINE, LONDON Volume IX. 1909 CAMBRIDGE AT THE UNIVERSITY PRESS LONDON: FETTER LANE,...»

«LETTERS FROM A STOIC ADVISORY EDITOR: BETTY RADICE LUCIUS ANNAEUS SENECA, statesman, philosopher, advocate and man of letters, was born at Cordoba in Spain around 4 B.C. Despite his relatively undistinguished background and ever-recurrent ill health, he rose rapidly to prominence at Rome, pursuing the double career in the courts and political life for which he had been trained. He began also quickly to acquire celebrity as an author of tragedies and of polished essays, moral, literary and...»

«Resource Guide For Pregnant and Parenting Teens Clark County Washington Compiled as a service of: GRADS Communities Collaborative Grant Funding for this Resource Guide was made possible under Grant SP1AH000015 from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Health, Office of Adolescent Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the...»

«LEONARDO DA VINCI ECVET-Projects May 2009 CONTENT Automotive Sector / Electrical Engineering • EUROPEAN CLASS IN TRUCK MAINTENANCE (133971-LLP-2007-SE-LMP) 3 • ECVET – compatibility of competencies. Sector related credit point system as a basis for the compatibility of competencies in the automotive sector. (DE/07/LLP-LdV/TOI/147031) 7 • MOVET (DE/08/LLP-LdV/TOI/147155) 11 • Vocational Qualification Transfer System (A/03/B/F/PP-158.034) 15 • Vocational Qualification Transfer II VQTS...»

«A Neuro-linguistic Programming-informed psychological approach to the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A case study and initial findings from a longitudinal investigation Authors: Megan Arroll and Anna Duschinsky Dr Megan Arroll is the Director of Research for The Optimum Health Clinic and holds a Visiting Research Fellowship at the University of East London. Her research interests include numerous medically-unexplained conditions such as ME/CFS, MdDS,...»

«Managing Spontaneous Volunteers in Times of Disaster Participant Materials Full-day Classroom Training Acknowledgements HandsOn Network extends special thanks to the following:  Adraine McKell of Hands On Manatee and Gigi Rolfes of Hands On Macon for the development of the Trainer Guide  Merilee White of Volunteer Florida for the use of her VRC model and materials  Faye Stone of the North Carolina Commission for the use of her Donations Management materials  Janet Pace of the...»

«Second Servings: Lesson for Second Grade Purpose To help students understand foods from each group which should be included in a daily diet as well as appropriate serving sizes of each food item Desired Outcomes The learner will develop and apply enabling strategies and skills to read and write. The learner will identify the serving sizes and number of daily servings needed from each food group of MyPlate. The learner will recognize and use appropriate units of measurement. The learner will...»

«Mercy Medical Center Community Health Needs Assessment and Implementation Plan Reviewed and approved by the Boards of Mercy Medical Center on June 25, 2013, and Catholic Health Services on July 29, 2013 1000 North Village Avenue Rockville Centre, NY • (516) 705-2525 www.MercyMedicalCenter.info I. Executive Summary A. New IRS Requirements The Affordable Care Act (ACA), enacted March 23, 2010, added new requirements that all not-forprofit hospitals, recognized as 501 (c) (3) organizations, are...»

«European Federation of Employees in Public Services Seminar Effects of the Financial Crisis on Local Public Services 01-03.12.2011 Abacus Tierpark Hotel, Berlin (Germany) Role of the social partners – the current situation Role of the social partners – in the light of renewing services to the public Health: are we heading towards the end of the quality of care? EUROFEDOP Seminar Report 1/8 European Federation of Employees in Public Services Opening speeches: Bert van Caelenberg...»

«Sound Advice This is an edited transcript of a telephone interview recorded in June 2009. Dr. Harvey Karp is a pediatrician and child development specialist. He is an assistant professor of pediatrics at the UCLA School of Medicine. Dr. Karp is the author of the books and DVDs Happiest Baby on the Block, and Happiest Toddler on the Block. Welcome, Dr. Karp. Q: Dr. Karp, are shots a plausible cause of autism? Dr. Karp: For more than 10 years, a growing course of activists and worried parents...»

«This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization, the International Labour Organization or the United Nations Environment Programme. Harmonization Project Document No. 2 CHEMICAL-SPECIFIC ADJUSTMENT FACTORS FOR INTERSPECIES DIFFERENCES AND HUMAN VARIABILITY: GUIDANCE DOCUMENT FOR USE OF DATA IN DOSE/CONCENTRATION–RESPONSE ASSESSMENT This project was conducted...»

«Case Report 1 Case Number 0020/15 2 Advertiser Bingle Insurance 3 Product Insurance 4 Type of Advertisement / media TV Free to air 5 Date of Determination 28/01/2015 6 DETERMINATION Dismissed ISSUES RAISED 2.1 Discrimination or Vilification Ethnicity 2.3 Violence Cruelty to animals 2.6 Health and Safety Unsafe behaviour DESCRIPTION OF THE ADVERTISEMENT The advertisement features a computer generated chimp. The chimp is blindfolded and we see it jump out of a plane whilst operating a lap-top...»





 
<<  HOME   |    CONTACTS
2016 www.thesis.xlibx.info - Thesis, documentation, books

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.